Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of RP901 tablets in knee osteoarthritis
CTR20230287Phase 2Suspended
- Sponsor
- Runjia Pharmaceutical
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RP901 in knee osteoarthritis (OA), sponsored by Runjia Pharmaceutical. Started Feb 2023; status: suspended.
02
Drugs
RP901
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on CTR20230287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230287.